医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL: Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University:New High-performance Cryopreservation Solution for Human ES/iPS Cells Used in Regenerative MedicineNotice of the Commencement of Sal

2015年08月26日 PM09:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

We hereby wish to inform you that, on August 20th 2015, in conjunction with the Institute for Frontier Medical Sciences, Kyoto University, ReproCELL announced to the press the release of “ReproCryo DMSO free”, our high-performance cryopreservation solution for human ES/iPS cells required in regenerative medicine, and start to commence sales of the product.

In regenerative medicine, the long-term freeze-preservation and banking of large quantities of human ES/iPS cells is an essential process. ReproCELL has succeeded in developing “ReproCryo DMSO free”, a new cryopreservation solution that is optimal for use in regenerative medicine. This cryopreservation solution consists solely of components scientifically proven to be highly safe, thus delivering a high degree of safety within the field of regenerative medicine. “ReproCryo DMSO free” also allows for the simultaneous freezing of a large quantity of cells, thus making the product suitable for automated processing. This technology represents a major contribution to the realization of regenerative medicine, which utilizes human ES/iPS cells.

The product was jointly developed with the Institute for Frontier Medical Sciences, Kyoto University in a development project for Japan Agency for Medical Research and Development (AMED), the national research and development corporation which was inaugurated in April this year.

Taking advantage of our strengths in global-scale advanced research networks and the superior technology of the ES/iPS cells we have cultivated thus far, our company group is advancing initiatives in the field of regenerative medicine. “ReproCryo DMSO free” holds an extremely important position as a product working for the promotion of regenerative medicine and is expected to make a significant contribution to the expansion of our group’s business.

For more information, visit: https://www.reprocell.com/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20150826005494/en/

CONTACT

ReproCELL, Inc. (JASDAQ Company code: 4978)
Chikafumi Yokoyama,
+81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田在日本和爱尔兰的制药工厂荣获2021年度设施类别奖
  • VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
  • 武田薬品、EGFRエクソン20挿入変異を伴う転移性非小細胞肺がんの治療薬モボセルチニブ(TAK-788)の新薬承認申請を米国FDAが優先審査に指定と発表
  • Dr. Reddy’s Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
  • Nanotronics Health Donates Hundreds of Non-Invasive Ventilators for COVID-19 Relief in India, in Collaboration with Transworld Group